AI Article Synopsis
- The study examined how different total injection times of intratympanic steroids affected hearing improvement in patients with idiopathic sudden sensorineural hearing loss (ISSNHL).
- A total of 191 patients were treated with both systemic prednisolone and intratympanic dexamethasone, with some receiving 4 injections and others receiving only 2.
- Results showed no significant difference in hearing outcomes between the two groups, suggesting that just 2 injections are sufficient and could reduce stress for patients.
Article Abstract
Objective: We studied the effect of intratympanic steroid administration with different total injection times on hearing outcomes in patients with idiopathic sudden sensorineural hearing loss (ISSNHL).
Methods: The subjects were 191 consecutive patients (192 ears) with ISSNHL (hearing level ≥40 dB, interval between onset and treatment ≤30 days). They received systemic prednisolone (100 mg followed by tapered doses) combined with intratympanic injection of dexamethasone (4 mg/ml). Intratympanic injection was performed 4 times (days 1, 2, 4, and 7) in 92 patients (92 ears) or 2 times (days 1 and 2) in 99 patients (100 ears). The hearing outcomes were evaluated at 1 week from the start of treatment and 1 to 2 months after the completion of treatment.
Results: There was no significant difference in hearing outcomes between the 4- and 2-injection groups at either time point. Multiple regression analysis also showed that the hearing level after treatment did not depend on the total number of intratympanic steroid injections.
Conclusion: These results indicate that a protocol using only 2 intratympanic steroid injections exerts a sufficient effect on the hearing outcomes of ISSNHL. This simplified treatment protocol would be greatly beneficial to relieve the physical and mental stress of patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0003489418755406 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sudden sensorineural hearing loss in diabetes mellitus patients receiving intra-tympanic steroid injections.
Am J Otolaryngol
December 2024
Department of Otorhinolaryngology & Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; School of Medicine, Chang Gung University, Taoyuan, Taiwan; Department of Otorhinolaryngology & Head and Neck Surgery, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
Background: Sudden sensorineural hearing loss is an acute hearing disorder typically managed using steroids. However, prognostic factors of diabetes mellitus (DM) patients undergoing intra-tympanic steroid injections (ITSIs) are unclear. We explored the prognostic factors for ITSI in DM patients with unilateral SSNHL.
View Article and Find Full Text PDFComparison between intratympanic injection of dexamethasone and methylprednisolone in idiopathic sudden sensorineural hearing loss: A randomized clinical trial.
Laryngoscope Investig Otolaryngol
December 2024
Hearing Disorders Research Center, Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences Tehran Iran.
Objective: To compare the hearing outcomes of patients with idiopathic sudden sensorineural hearing loss after intratympanic (IT) injection of methylprednisolone and dexamethasone.
Study Design: Randomized case-controlled clinical trial.
Methods: Seventy-five patients diagnosed with idiopathic sensorineural hearing loss were randomly divided into two groups based on therapy.
Plasma Concentration as a Proxy for Perilymph Drug Levels: Preclinical and Clinical Dexamethasone Measures with a Long-Acting Formulation for Precise Delivery to the Round Window Membrane.
Otol Neurotol
January 2025
Turner Scientific, Inc., Jacksonville, Illinois, USA.
Objective: To use animal pharmacokinetic data and FluidSIM modeling to estimate human dexamethasone perilymph concentrations from plasma concentration measurements over time following a single intratympanic administration of SPT-2101.
Study Design: Perilymph and plasma dexamethasone concentrations were measured in guinea pigs and African green monkeys over 3 to 6 weeks post-intratympanic administration of SPT-2101. Plasma concentrations of dexamethasone were measured in Ménière's disease patients post-intratympanic administration of SPT-2101.
Management of sudden sensorineural hearing loss: A time-critical diagnosis.
Aust J Gen Pract
November 2024
BA (Psych), MBBS (Hons), FRACS (OHNS), Consultant Ear Nose and Throat Surgeon, Department of Otolaryngology Head and Neck Surgery, Sunshine Coast University Hospital, Sunshine Coast, Qld.
Background: Sudden sensorineural hearing loss (SSNHL) is an otologic emergency requiring urgent medical attention and care.
Objective: This article, based on up-to-date evidence and clinical guidelines, aims to equip general practitioner (GP) specialists with a structured and practical approach to SSNHL management, emphasising the need for prompt evaluation and appropriate interventions. From initial evaluation to treatment strategies and follow-up, this guide offers a step-by-step framework to optimise patient care and improve outcomes in patients suffering SSNHL.
Up-regulation of HIF-1α in refractory sudden sensorineural hearing loss.
Acta Otorhinolaryngol Ital
October 2024
Department of Otolaryngology-Head and Neck Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
Objectives: To investigate the expression of hypoxia-inducible factor-1α (HIF-1α) in patients with refractory sudden sensorineural hearing loss (SSNHL).
Material And Methods: Thirty patients with refractory SSNHL were treated with intratympanic methylprednisolone perfusion (IMP) for 10 days. Expression of HIF-1α and histone deacetylase 2 (HDAC2) was evaluated in peripheral blood mononuclear cells (PBMCs) and .
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!